U.S. Patent and Trademail.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10711462
Filing Date		2004-09-20
First Named Inventor	Bogda	an Radu
Art Unit		2885
Examiner Name	David	J. Makiya
Attorney Docket Numb	er	MASL-57

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Pate of cited Docu	entee or Applicant iment	Releva	Columns,Lines where nt Passages or Releva s Appear
	1	4875143	A	1989-10	-17	Fernandez			
	2	6000493	A	1999-12-	-14	Chen			
	3	6158869	A	2000-12-	-12	Barnes, Jr.			
	4	6270229	B1	2001-08	-07	Chien			
If you wisl	h to a	dd additional U.S. Pater	t citatio	n informa	ation pl	ease click the	Add button.		Add
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove
Examiner Initial*	rer Cite No Publication Number Kind Code ¹ Publication Date Name of Patentee or Appl of cited Document			Releva	Columns,Lines where nt Passages or Releva s Appear				
	1								
If you wisi	h to a	dd additional U.S. Publi:	shed Ap	plication	citation	n information p	olease click the Ad	d button	
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date Name of Patent Applicant of cite Document		e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10711462
Filing Date		2004-09-20
First Named Inventor	Bogda	an Radu
Art Unit		2885
Examiner Name David		J. Makiya
Attorney Docket Number		MASL-57

	1												
If you wish to add additional Foreign Patent Document citation information please click the Add button Add													
NON-PATENT LITERATURE DOCUMENTS Remove													
Examiner Initials*	Cite No	(boo	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city, and/or country where published.								T6		
	1		LUKS, JEREMY AUSTIN (EXAMINER), US Patent and Trademark Office, Office Action issued in related application serial number 10/711,463 dated 03/21/07.										
If you wish to add additional non-patent literature document citation information please click the Add button Add													
EXAMINER SIGNATURE													
Examiner	Examiner Signature Date Considered												
*EVAMINED: Initial if reference considered subother or not citation is in conformance with MPER COL. Draw line through a													

See Kind Codes of USPTO Petent Documents at invest ISPTO_GDI/cr MPEP 601.04. 2 Enter office that issued the document, by the involved cold (WIPO Standard S13.) 3 For Lapraence parter foundment, the advicable on the peer of the Emperor may precede the serial revision of the parter of the parter of the Emperor may precede the serial revision of the parter of the par

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10711462			
Filing Date		2004-09-20			
First Named Inventor	Bogda	Bogdan Radu			
Art Unit		2885			
Examiner Name	David	J. Makiya			
Attorney Docket Number		MASL-57			

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and :	1 98 t	o make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.57(e)(1).

OR

That no item of information contained in the information disclosure statement, was cited in a communication from a design patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to it is individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ Nor

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/William R. Allen/	Date (YYYY-MM-DD)	2007-04-04
Name/Print	William R. Allen	Registration Number	48389

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol field not by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. 107 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.